ZYXI Stock Overview
Designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Zynex, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.26 |
| 52 Week High | US$13.77 |
| 52 Week Low | US$7.15 |
| Beta | 0.54 |
| 11 Month Change | -1.20% |
| 3 Month Change | 0.85% |
| 1 Year Change | -13.42% |
| 33 Year Change | -29.35% |
| 5 Year Change | -13.47% |
| Change since IPO | 286.64% |
Recent News & Updates
Zynex's (NASDAQ:ZYXI) Returns On Capital Not Reflecting Well On The Business
Nov 12
Zynex (NASDAQ:ZYXI) Seems To Use Debt Quite Sensibly
Oct 26Recent updates
Zynex's (NASDAQ:ZYXI) Returns On Capital Not Reflecting Well On The Business
Nov 12Zynex (NASDAQ:ZYXI) Seems To Use Debt Quite Sensibly
Oct 26Zynex, Inc.: 2025 Looks Like A Brighter Year
Oct 09With Zynex, Inc. (NASDAQ:ZYXI) It Looks Like You'll Get What You Pay For
Jul 31Earnings Update: Here's Why Analysts Just Lifted Their Zynex, Inc. (NASDAQ:ZYXI) Price Target To US$19.88
May 03Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts
Mar 03Why Investors Shouldn't Be Surprised By Zynex, Inc.'s (NASDAQ:ZYXI) P/E
Jan 24Is Zynex (NASDAQ:ZYXI) Using Too Much Debt?
Aug 03Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?
Mar 30Should You Be Adding Zynex (NASDAQ:ZYXI) To Your Watchlist Today?
Jan 23Short Squeeze Candidate With Low PEG Ratio: Zynex
Oct 05Zynex begins enrollment in blood loss detection trial for CM-1600 monitoring system
Sep 21These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely
Aug 02Zynex Cures The Pain Of Its Shareholders: Q2 Results
Aug 01Zynex: Upside Looks Well Priced In, Efficiency Headwinds Remain
Jul 25Is Zynex, Inc. (NASDAQ:ZYXI) Trading At A 46% Discount?
Jul 12Zynex June and Q2 orders hit all-time high, re-affirms Q2 and FY22 guidance
Jul 11Shareholder Returns
| ZYXI | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 5.9% | 1.5% | 2.2% |
| 1Y | -13.4% | 20.9% | 31.7% |
Return vs Industry: ZYXI underperformed the US Medical Equipment industry which returned 20.9% over the past year.
Return vs Market: ZYXI underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| ZYXI volatility | |
|---|---|
| ZYXI Average Weekly Movement | 7.0% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ZYXI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ZYXI's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 1,100 | Thomas Sandgaard | www.zynex.com |
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products.
Zynex, Inc. Fundamentals Summary
| ZYXI fundamental statistics | |
|---|---|
| Market cap | US$258.27m |
| Earnings (TTM) | US$4.82m |
| Revenue (TTM) | US$193.67m |
54.5x
P/E Ratio1.4x
P/S RatioIs ZYXI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZYXI income statement (TTM) | |
|---|---|
| Revenue | US$193.67m |
| Cost of Revenue | US$39.34m |
| Gross Profit | US$154.32m |
| Other Expenses | US$149.50m |
| Earnings | US$4.82m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.15 |
| Gross Margin | 79.69% |
| Net Profit Margin | 2.49% |
| Debt/Equity Ratio | 163.0% |
How did ZYXI perform over the long term?
See historical performance and comparison